Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?—insights and limitations from the MARIPOSA study
Edyta Maria Urbanska, Eric Santoni-Rugiu, Morten Grauslund, Jens Benn Sørensen · 2026
Read Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?—insights and limitations from the MARIPOSA study by Edyta Maria Urbanska, Eric Santoni-Rugiu, Morten Grauslund, Jens Benn Sørensen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266878.txt.
Description
Edyta Maria Urbanska and co-authors ask in 2026 whether two third-generation targeted drugs for EGFR-mutant lung cancer, lazertinib and osimertinib, perform alike when used alone. Their question arises from the three-arm MARIPOSA trial, which mainly tested a drug combination against osimertinib. Because the trial also included a lazertinib-only arm, a direct comparison became possible.
The groups were well balanced, with similar shares of the two common EGFR mutations and similar rates of brain spread at entry. The authors weigh an exploratory analysis comparing the single drugs, while noting that formal statistical power was reserved for the main comparison. Their discussion helps readers judge how much of the combination's success comes from lazertinib itself.
Catalog record
| CREATOR | Edyta Maria Urbanska, Eric Santoni-Rugiu, Morten Grauslund, Jens Benn Sørensen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |